PAXMAN publishes newsletter with information about its strong progress in the USA, Mexico and globally
PAXMAN has today published a new issue of its newsletter aimed at shareholders, investors and other interested parties. For the first time, the newsletter is published in both Swedish and English.
This issue highlights the company’s strong interim report, an increased focus on enrolling more patients in the USA, the ongoing installation of the first systems in Mexico and a new long-term study confirming that scalp cooling can used to protect against permanent hair loss after chemotherapy.
To read the newsletter, and subscribe to receive upcoming issues, follow this link:
PAXMAN’s newsletter, initially published every two months, is a part of the company’s effort to strengthen its market communication together with the IR communication agency Honeybadger. Every published issue of the newsletter will be available on PAXMANs website for investors, www.paxman.se. The company encourages feedback and requests on topics for upcoming issues of the newsletter.
For further information, please contact:
Richard Paxman, CEO
Tel: +44 7968 020641
The Paxman Scalp Cooling System has been developed by the Paxman family to reduce hair loss in breast cancer patients undergoing chemotherapy. The concept behind the system came when the mother of four, Sue Paxman, experienced first-hand the trauma of chemotherapy-induced hair loss. With more than 3,000 systems delivered in to hospitals, clinics and treatment centres around the world, PAXMAN is the leading supplier of Scalp Cooling technology. PAXMAN’s scalp-cooling cap is made from lightweight, biocompatible silicone that is soft and flexible, providing a snug yet comfortable fit during treatment. PAXMAN AB (publ) has its headquarters in Karlshamn (Sweden), with subsidiaries in Huddersfield (UK) and Houston, Texas (US)
The PAXMAN share is listed on Nasdaq First North. FNCA Sweden AB is the company’s Certified Adviser.